Glaukos (GKOS) to Release Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS - Get Free Report) is expected to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect Glaukos to post earnings of ($0.33) per share and revenue of $102.78 million for the quarter. Glaukos has set its FY 2025 guidance at EPS.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Price Performance

Shares of GKOS opened at $89.76 on Wednesday. The firm has a market cap of $5.08 billion, a PE ratio of -31.27 and a beta of 0.88. Glaukos has a 52-week low of $77.91 and a 52-week high of $163.71. The business's 50 day moving average price is $105.86 and its two-hundred day moving average price is $130.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Insider Transactions at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Truist Financial reduced their price target on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating for the company in a report on Friday, April 11th. Stifel Nicolaus boosted their target price on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. Wells Fargo & Company upped their price target on Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Needham & Company LLC raised their price objective on Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Mizuho lowered their target price on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $156.17.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.